Oflobid Tablets 400Mg

Brand : hilton pharma

Rs. 296.40

Rs. 312.00

|

QUICK DELIVERY

Oflobid Tablets Specification

Requires Prescription (YES/NO)

Yes

Generics

Ofloxacin

Used For

Bacterial Infection

How it works

Ofloxacin inhibits bacterial DNA replication by inhibiting bacterial topoisomerases, particularly DNA gyrase and topoisomerase IV. It is active after oral administration.

Oflobid Tablets Usage And Safety

Dosage

Ofloxacin

Side Effects

GI upset , Skin reactions , CNS disturbances , reports of hypersensitivity reactions , suicidal thoughts and behaviour, peripheral neuropathy , tendinitis, tendon rupture. Inj : Pain at inj.siite, thrombophlebitis.

Drug Interactions

Sucralfate , corticosteroid , NSAIDs e.g. ibuprofen or diclofenac, or theophylline , glibenclamide , cimetidine , probenecid , methotrexate , warfarin , didanosine , furosemide.

Indication

Ofloxacin is an antibiotic that can be used to treat a variety of different infections .

When not to Use

Do not take Ofloxacin: • If you are allergic to ofloxacin or any of the other ingredients of this medicine . Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue. • If you have previously had an allergic reaction to another quinolone antibiotic e.g. ciprofloxacin or norfloxacin. • If you suffer from epilepsy or are at risk of fits .

Oflobid Tablets Precautions

Precaution

The use of ofloxacin should be avoided in patients who have experienced serious adverse reactions in the past when using quinolone or fluoroquinolone containing products . Treatment of these patients with ofloxacin should only be initiated in the absence of alternative treatment options and after careful benefit/risk assessment .

Oflobid Tablets Warnings

Warning 1

Methicillin-resistant S. aureus is very likely to possess co-resistance to fluoroquinolones, including ofloxacin. Therefore, ofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to ofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA-infections are considered inappropriate).

Warning 2

The most common pathogen involved in urinary tract infections varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in E. coli to fluoroquinolones.

Warning 3

Due to increase in resistance to N. gonorrhoeae, ofloxacin should not be used as empirical treatment option in suspected gonococcal infection unless the pathogen has been identified and confirmed as susceptible to ofloxacin. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.